• Surgical bleeding, particularly problematic bleeding, is frequently associated with increased morbidity, mortality and economic burden. 1, 2, 3 • Hepatic surgical procedures are associated with significant risks for bleeding that can be particularly problematic due to diffuse, parenchymal "oozing". 4, 10 • Limitations of currently available topical hemostats include lack of efficacy on first attempt, lack of options in problematic bleeding, and sub-optimal ease-of-use. 5, 6 • EVARREST TM Fibrin Sealant Patch is a novel, bioabsorbable hemostatic product comprised of biological components (i.e., human fibrinogen and thrombin) and a flexible patch component (oxidized regenerated cellulose (ORC) and polyglactin (PG910)). 7
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• The clinical benefits of EVARREST TM have been demonstrated in several randomized controlled trials (RCTs). 8, 9, 10 • Literature suggests that more efficacious hemostats may avert hospital resources and offset upfront acquisition costs. 5, 6, 11, 12 
Design
• A budgetary impact model was developed that quantified the 30-day cost impact of EVARREST TM versus SOC from a German inpatient hospital perspective.
• The model can incorporate various market-share scenarios; however, for the purpose of this analysis, 100% EVARREST TM uptake is compared to 100% SOC uptake.
• The model framework is outlined in Figure 1 
Sensitivity Analysis Results
• A series of sensitivity analyses were conducted, using the primary analysis as the reference case for comparison.
-Results were relatively robust to most assumptions, predicting cost-savings with use of EVARREST TM versus SOC for the hospital or only a small cost impact (Table 3 ).
• One-way sensitivity analyses varying costs of all the inputs by ±20% suggested that the acquisition cost of EVARREST TM and the operating room costs were drivers in both the primary and secondary analyses, and hospital length of stay was also a driver in the secondary analysis ( Figure 3 ).
-Results of the one-way sensitivity for the primary analysis demonstrated cost offsets for all parameters even when adjusted by ±20% (Figure 3a ). -When costs were adjusted by ±20% in the secondary analysis, all of the results were still costs savings ( Figure 3b ).
• A study was conducted to estimate the 30-day cost impact of the EVARREST TM novel fibrin sealant patch versus standard of care (SOC) in parenchymal bleeding during elective hepatic surgery from the Germany inpatient hospital perspective.
Figure 1. Model Framework Model Inputs and Analyses
• Key resources included in the model analyses were collected from a multi-centre RCT comparing the safety and efficacy of EVARREST TM versus SOC in parenchymal bleeding during elective hepatic surgery.
-SOC was comprised of 61% manual compression, 34% manual compression with a topical absorbable hemostat [e.g., Surgicel], 5% other [e.g., argon beam]) • Resources were costed in Euros and inflated to 2013 costs where possible.
• Model inputs are outlined in Table 1 .
Sensitivity Analyses
• Alternate assumptions regarding resource use and costs were evaluated relative to the primary and secondary analyses to assess the robustness of the results to changes in inputs.
• One-way sensitivity analyses were performed by varying cost inputs by ± 20% to test for drivers of the model. • This analysis suggests that EVARREST TM may result in cost savings in hepatic parenchymal bleeding compared with SOC in German hospital settings while meeting important unmet need for controlling bleeding in hepatic surgery.
• Results were robust to several alternative assumptions in sensitivity analyses.
• Key limitations of the current analysis include:
-Differences in trial reported resource use often did not reach statistical significance. However, resource use was not the primary endpoint of these trials and thus statistical power calculations were not taken with this aim.
•
The strong trends shown in the data for the resource outcomes suggest that an adequately powered study with these as primary endpoints may achieve positive results.
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• The primary analysis predicted that EVARREST TM acquisition cost is offset due to less resoure use, with cost impact reduced to €330 per patient vs. SOC (Figure 2a ).
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